<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The Obstetric APS Task Force of the 13th International Congress identified and discussed five general topics within 'Obstetric' <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">Antiphospholipid Syndrome</z:e> (APS) that contained areas of controversy or uncertainty: recurrent early <z:e sem="disease" ids="C0000786" disease_type="Disease or Syndrome" abbrv="">miscarriage</z:e> (REM), fetal <z:hpo ids='HP_0011420'>death</z:hpo>, delivery &lt;34 weeks for <z:e sem="disease" ids="C0341950,C0156669" disease_type="Disease or Syndrome" abbrv="">severe preeclampsia</z:e> or <z:mp ids='MP_0006372'>placental insufficiency</z:mp>, postpartum care, and long-term implications and care </plain></SENT>
<SENT sid="1" pm="."><plain>The Task Force concluded that the frequency with which women with REM have a high titer of <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> (aPL) or <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> (LA) is somewhat controversial, especially with regard to the diagnostic titers required by the current international criteria for APS </plain></SENT>
<SENT sid="2" pm="."><plain>Also, treatment trials involving <z:chebi fb="5" ids="28304">heparin</z:chebi> differ from one another with regard to the patients included and the outcomes achieved </plain></SENT>
<SENT sid="3" pm="."><plain>Similarly, the frequency with which women with fetal <z:hpo ids='HP_0011420'>death</z:hpo> or delivery &lt;34 weeks for <z:e sem="disease" ids="C0341950,C0156669" disease_type="Disease or Syndrome" abbrv="">severe preeclampsia</z:e> or <z:mp ids='MP_0006372'>placental insufficiency</z:mp> have a high titer of aPL or LA is poorly defined, and there is no level I evidence to guide treatment in either group </plain></SENT>
<SENT sid="4" pm="."><plain>Suggestions for future studies with regard to both REM and fetal <z:hpo ids='HP_0011420'>death</z:hpo> or delivery &lt;34 weeks for <z:e sem="disease" ids="C0341950,C0156669" disease_type="Disease or Syndrome" abbrv="">severe preeclampsia</z:e> or <z:mp ids='MP_0006372'>placental insufficiency</z:mp> were discussed and are outlined below </plain></SENT>
<SENT sid="5" pm="."><plain>Postpartum and long-term care in women with APS diagnosed solely for obstetric criteria has been largely guided by expert opinion, and systematic evaluations of these populations would be welcome </plain></SENT>
</text></document>